Farmacoeconomía de la terapia biológica de las espondiloartropatías
PDF

Palabras clave

espondiloartropatía
farmacoeconomía
terapia biologica

Cómo citar

García C., J. C. (2016). Farmacoeconomía de la terapia biológica de las espondiloartropatías. Revista Colombiana De Enfermería, 5, 29–40. https://doi.org/10.18270/rce.v5i5.1422

Resumen

Las espondiloartropatías (EAS) son un grupo de enfermedades reumatológicas crónicas e inflamatorias. El diagnóstico de estas patologías frecuentemente es tardío; su curso evolutivo es progresivo, con el consecuente deterioro funcional y discapacidad, con compromiso articular que conlleva a la disminución en la calidad de vida con un alto impacto socioeconómico. La mayoría de los estudios farmacoeconómicos se enfocan en los aspectos de la sociedad o del proveedor de los servicios de salud, y sólo una minoría toma en cuenta la perspectiva del paciente, de donde se pueden estimar los recursos médicos directos e indirectos que el paciente y su familia destinan al tratamiento de la enfermedad. La terapia biológica ha demostrado control de todos los aspectos de la actividad de la enfermedad, incluyendo reactantes de fase aguda, dolor y rigidez, capacidad funcional, movilidad espinal, artritis periférica y entesitis.

https://doi.org/10.18270/rce.v5i5.1422
PDF

Citas

1.
González LA, Londoño JD, Valle RR. Disgnóstico
temprano de las espondiloartropatías. Revista Colom
-
biana de Reumatología. 2005; 12 (3): 241-262.
2.
Valle RR, Jáuregui E, Otero W, Vélez P et ál. Recomen
-
daciones del Comité de Expertos de la Asociación
Colombiana de Reumatología para el empleo de la
terapia biológica en las espondiloartropatías. Revista
Colombiana de Reumatología. 2005; 12 (2): 95-106.
3.
Londoño JD, Valle RR. Es hora de tomar conciencia sobre
el tratamiento de las espondiloartropatías. Editorial Revista
Colombiana de Reumatología. 2003; 10 (4): 245-248
4.
Collantes E, Muñoz E. En: Valle RR, Londoño JD Eds.
Espondiloartropatías: Validación de criterios diagnós
-
ticos y de clasificación de las espondiloartropatías.
Primera edición. Asociación Colombiana de Reumato
-
logía. 2007: 119-128
5.
Khan MA. Thoughts concerning the early diagnosis of
ankylosing spondylitis. Clin Exp Rheumatol 2002; 20
(Suppl.
28): S6-S10.
6.
Erturk M, Alaca R, Tosun E, Duruöz MT.
Evaluation
of the Amor and ESSG classification criteria for spon
-
dylarthropathies in a turkish population. Rev Rhum
(Engl Ed.) 1997; 64: 293-300.
7.
Boyer GS, Templin DW, Bowler A et ál.
Spondylar-
Spondylar
-
thropathy in the community: Clinical syndromes and
disease manifestations in alaskan eskimo populations.
J Rheumatol 1999; 26: 1537-1544.
8.
Amor B, Dougados M, Mijiyawa M. Critères de classica
-
tion des spondylarthropathies. Revue du Rhumatis et
des Maladies Osteoarticulaire. 1990; 57: 85-89.
9.
Calin A, Porta J, Fries JF, Schurmann DJ. Clinical history
as a screening test for ankylosing spondylitis. JAMA
1977; 237: 2613-2614.
10.
D`Orazio A, Correa MA, Rosemffet M, cols. Terapia
biológica en espondiloartropatías seronegativas:
Experiencia en 21 pacientes. Revista Argentina de
Reumatología. 18 (2): 33-37.
11.
Clegg D. Treatment of ankylosing spondylitis. J Rheu
-
matol 2006; 33: 24-31.
12.
Ruof J, Hûlsemann JL, Stucki L. Evaluation of costs
in rheumatic diseases: A literature review. Curr Opin
Rheumatol 1999; 11: 104-109.
13.
Lapsley HM, March LM, Tribe KL, Cross MJ, et ál. Living
with rheumatoid arthritis: Expenditures health status
and social impact on patients. Ann Rheum Dis 2002;
61: 818-821.
14.
Torres AC, Knaul FM. Determinantes del gasto de
bolsillo en salud e implicaciones para el aseguramiento
universal en México: 1992-2000. Calidoscopio de la
Salud 2004: 209-225.
15.
Boonen A, Van der Heijde D, Landewe R, et ál. Costs of
ankylosing spondylitis in three European countries: The
patients perspective. Ann Rheum Dis 2003; 62: 741-747.
16.
Mould-Quevedo J, Pelaez-Ballestas I, Vazquez-Mellado
J, et ál. El costo de las principales enfermedades reumá
-
ticas inflamatorias desde la perspectiva del paciente en
Mexico. Gac Med Mex 2008; 144: 225-231.
17.
Barlow JH, Wright CC, Williams B, et ál. Work disabi
-
lity among people with ankylosing spondylitis. Arthritis
Care Res 2001; 45: 429-437.
18.
Ariza-Ariza R, Henandez-Cruz B, Navarro-Sarabia F.
Physical function and health-related quality of life of
spanish patients with ankylosing spondylitis. Arthritis
Care Res 2003; 49: 483-487.
19.
Ara RM, Packham JC, Haywood KL. The direct health
-
care costs associated with ankylosing spondylitis
patients attending a UK secondary care rheumatology
unit. Rheumatology 2008; 47:68-71.
20.
Khan MA. Ankylosing spondylitis: Clinical aspects. In:
Calin A, Taurog J, eds. The spondyloarthritides. Oxford:
Oxford University Press, 1998.
21.
Van der Heijde D, Djikmans B, Geusens P et ál.
Effi-
Effi
-
cacy and safety of infliximab in patients with ankylosing
spondylitis. Results of a randomized, placebo – contro
-
lled trial (ASSERT). Arthritis Rheum 2005; 52: 582-91.
22.
Davis JC Jr, Van der Heijde D, Braun J et ál. Enbrel
ankylosing spondylitis study group. Recombinant
human tumour necrosis factor receptor etanercept for
treating ankylosing spondylitis: A randomized contro
-
lled trial. Arthritis Rheum 2003; 48: 3230-6.
23.
Van der Heijde D, Kivitz A, Schiff MH et ál. Efficacy
and safety of adalimumab in patients with ankylo
-
sing spondylitis. Results of a multicentre, andomized,
doubleblind, placebo-controlled trial. Arthritis Rheum
2006; 54: 2136-46.
24.
Davis JC, van der Heijde, Dougadaos M, Wooley JM.
Reductions in health-related quality of life in patients
with ankylosing spondylitis and mprovements with
etanercept therapy.
Arthritis Rheum 2005; 53: 494-501.
25.
Davis JC Jr, Revicki D, van der Heijde DM et ál.
Health-
related quality of health outcomes in patients with
active ankylosing spondylitis treated with adalimumab:
Results from a randomized controlled study. Arthritis
Rheum 2007; 57: 1050-7.
26.
Braun J, Baralikos X, Brandt J et ál.
Persistent clinical
response to the anti-TNFalpha antibody infliximab in
patients with ankylosing spondylitis over 3 years. Rheu
-
matology 2005; 44: 670-6.
27.
Bresnihan B, Cunnane G. Infection complications asso
-
ciated with the use of biologic agents. Rheum Dis Clin
North Am 2003; 29: 185-202.
28.
Baralikos X, Listing J, Rudwaleit M et ál..
Radiographic
progression in patients with ankylosing spondylitis after 2
years of treatment with the tumour necrosis factor alpha
antibody Infliximab. Ann Rheum Dis 2005; 64: 1462-6.
29.
Garret S, Jenkinson T, Kennedy LG, Whitelock H, Gains
-
ford P, Calin A. A new approach to defining disease
status in ankylosing spondylitis. The BATH Ankylosing
Spondylitis Disease Activity Index. J Rheumatol 1994;
21: 2286-91.
30.
Calin A, Garret S, Whitelock H et ál. A new approach
to defining functional ability in ankylosing spondylitis:
The development of the BATH Ankylosing Spondylitis
Functional Index. J Rheumatol 1994; 21: 2281-85.
31.
Jenkinson TR, Mallory PA, Whitelock HC, Kennedy LG,
Garret SL, Calin A. Defining spinal mobility in ankylo
-
sing spondylitis (AS). The Bath AS Metrology Index. J
Rheumatol 1994; 21: 1694-8.
32.
Braun J, Baraliakos X, Listing J, Fritz C, et ál. Persis
-
tent clinical efficacy and safety of anti-tumour necrosis
factor a therapy with infliximab in patients with ankylo
-
sing spondylitis over 5 years: evidence for different
types of response. Ann Rheum Dis. 2008; 67: 340-345.
33.
Brandt J, Khariouzov A, Listing J, et ál..
Six month result
of a double-blind, placebo-controlled trial of Etanercept
in patients with active ankylosing spondylitis. Arthritis
Rheum 2003; 48: 1667-75.
34.
Brandt J, Listing J, et ál..
Long-Term efficacy and safety
of etanercept after readministration in patients active
ankylosing spondylitis. Rheumatology Oxford 2005;
44: 342-8.
35.
Davis JC Jr, van der Heijde D, Braun J, et ál. Recombinant
human tumor necrosis factor receptor (etanercept) for
treating ankylosing spondylitis: Randomized, contro
-
lled trial. Arthritis Rheum 2003; 48: 3230-6.
36.
Calin A, Dijkmans BA, Emery P, et ál. Outcomes of a
multicentre randomized clinical trial of etanercept to treat
ankylosing Spondylitis. Ann Rheum Dis 2004; 63: 1594-600.
37.
Davis JC Jr, van der Heijde D, Braun J, et ál. Sustained
durability and tolerability of etanercept in ankylosing
Spondylitis for 96 week. Ann Rheum Dis 2005; 64: 1557-62.
38.
Braun J, Brandt J, Listing J, et ál.
Treatment of active
ankylosing spondylitis with infliximab: A randomized
controlled multicentre trial. Lancet 2002; 359: 1187-93.
39.
Van Den Bosch F, Kruithof E, Baeten D, et ál. Randomized
double-blind comparison of chimeric monoclonal anti
-
body to tumor necrosis factor alpha (Infliximab) versus
placebo in active spondylarthropathy. Arthritis Rheum
2002; 46: 755-65.
40.
Van der Heijde D, Dijkmans B, Geusens P, et ál.. Effi
-
cacy and safety of Infliximab in patines with ankylosing
spondylitis: Results of a randomized, placebo-contro
-
lled trial (ASSERT).
Arthritis Rheum 2005; 52: 582-91.
41.
Braun J, Brandt J, Listing J, et ál.
Long term efficacy
and safety of infliximab in the treatment of Ankylosing
Spondylitis: An open, observational, extension study
of a three-month, randomized, placebo.controlled trial.
Arthritis Rheum 2003; 48: 2224-33.
42.
Braun J, Brandt J, Listing J, et ál.
Two year maintenance
of efficacy and safety of Infliximab in the treatment of
Ankylosing Spondylitis.
Ann Rheum Dis 2005; 64: 229-34
43.
Braun J, Baraliakos X, Brandt J, et ál..
Persistent clinical
response to the anti-TNF-alpha antibody Infliximab in
patiens with Ankylosing Spondylitis over 3 years. Rheu
-
matology Oxford 2005; 44: 670-6.
44.
Van der Heijde D, Kivitz A, et ál.. Efficacy and safety
of Adalimumab in patients with ankylosing spondylitis.
Arthritis Rheum 2006; 54: 2136-46.
45.
Baraliakos X, Davis J, Tsuji W, Braun J. Magnetie reso
-
nance imaging examinations of the spine in patiens
with ankylosing spondylitis before and after therapy
with the tumor necrosis factor alpha receptor fusion
protein etanercept. Arthritis Rheum 2005; 52: 121-23.
46.
Wailoo A, Bansback N, Chilcott J. Infliximab, etanercept
and adalimumab for the treatment of ankylosing spon
-
dylitis: Cost-effectiveness evidence and NICE guidance.
Editorial. Rheumatology 2008; 47: 119-120.
47.
Furst DE, Keystone EC, Kirkham B, Fleischmann R, et
ál. Updated consensus statement on biological agents
for the treatment of rheumatic diseases, 2008. Ann
Rheum Dis 2008; 67; iii2-iii25.
48.
Braun J, Davis J, Dougados M, Sieper J, van der Linden
S, van der Heijde D. ASAS Working Group. First update
of the international ASAS consensus statement for
the use of anti-TNF agents in patients with ankylosing
spondylitis. Ann Rheum Dis 2006; 65: 316-20.
49.
Bansback N, Maetzel A, Drumond M, Boonen A, et ál.
Consideration and preliminary proposals for defining a
reference case for economic evaluations in ankylosing
spondylitis. J Rheumat 2007; 34 (5): 1178-1183.
50.
Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck
B, Burge DJ. Etanercept in the treatment of psoriatic
arthritis and psoriasis: a randomised trial. Lancet 2000;
356: 385-90.
51.
Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB,
Ory P, et ál. Etanercept treatment of psoriatic arthritis:
Safety, efficacy, and effect on disease progression.
Arthritis Rheum 2004; 50: 2264-72.
52.
Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory
P, et ál. Continued inhibition of radiographic progression
in patients with psoriatic arthritis following 2 years of
treatment with etanercept. J Rheumatol 2006; 33: 712-21.
53.
Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler
A, Guzzo C, et ál. Infliximab improves signs and symp
-
toms of psoriatic arthritis: Results of the impact 2 trial.
Ann Rheum Dis 2005; 64: 1150-7.
54.
Antoni CE, Kavanaugh A, van der Heijde D, Beutler A,
Keenan G, Zhou B, et ál. Two-year efficacy and safety
of infliximab treatment in patients with active psoriatic
arthritis: Findings of the Infliximab Multinational
Psoriatic Arthritis Controlled Trial (IMPACT). J Rheu
-
matol 2008; 35: 869-76.
55.
Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM,
Steinfeld SD, Choy EH, et ál.. Adalimumab for the
treatment of patients with moderately to severely
active psoriatic arthritis: Results of a double-blind,
randomized, placebo-controlled trial. Arthritis Rheum
2005; 52: 3279-89.
56.
Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp
JT, Ory PA, et ál. Adalimumab for long-term treatment
of psoriatic arthritis: Forty-eight week data from the
adalimumab effectiveness in psoriatic arthritis trial.
Arthritis Rheum 2007; 56: 476-88.
57.
Kimball AB, Jackson JM, Sobell JM, Boh EE, Grekin S,
Pharmd EB, et ál. Reductions in healthcare resource
utilization in psoriatic arthritis patients receiving
etanercept therapy: Results from the educate trial. J
Drugs Dermatol 2007; 6: 299-306.
58.
Kavanaugh A, Antoni C, Mease P, Gladman D, Yan S,
Bala M, et ál. Effect of Infliximab therapy on employ
-
ment, time lost from work, and productivity in patients
with psoriatic arthritis. J Rheumatol 2006; 33: 2254-9.
59.
Bravo Vergel Y., N. Hawkins S., Claxton K., Asseburg
C., et ál. The cost-effectiveness of etanercept and
infliximab for the treatment of patients with psoriatic
arthritis. Rheumatology 2007; 46: 1729-1735.
60.
Schnarr S., Kuipers J.G., Zeidler H. Anti-tumour
necrosis factor (TNF)-therapy in undifferentiated spon
-
dyloarthropathy. Clin Exp Rheumatol 2002; 20 (Suppl.
28): S126-S129.
61.
Bakker C, Hidding A, van der Linder S, van Doorslaer E.
Cost effectiveness of group physical therapy compared
to individualized therapy for ankylosingspondylitis: a
randomised clinical trial. J Rheumatol 1994; 21: 264-268.
62.
Ward MM. Functional disability predicts total cost in
patients with ankylosing spondylitis. Arthritis Rheum
2002; 46: 223-231.
63.
Valle R, Jáuregui E, Otero W. Guías para el empleo de
terapia biológica en las espondiloartropatías. Asocia
-
cion Colombiana de Reumatología. 2005: 1-29

Descargas

Los datos de descargas todavía no están disponibles.